OXBOF (Oxford BioDynamics) 1-Year Share Buyback Ratio: -119.20% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Oxford BioDynamics 1-Year Share Buyback Ratio?

Oxford BioDynamics OXBOF +6.67% 1-Year Share Buyback Ratio is -119.20 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 146 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 93.15% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Oxford BioDynamics's current 1-Year Share Buyback Ratio was -119.20%.

OXBOF's 1-Year Share Buyback Ratio is ranked worse than
93.15% of 146 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.8 vs OXBOF: -119.20

Oxford BioDynamics  (OTCPK:OXBOF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Oxford BioDynamics 1-Year Share Buyback Ratio Related Terms

OXBOF vs TMO, DHR, NTRA: 1-Year Share Buyback Ratio Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics 1-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's 1-Year Share Buyback Ratio falls into.


Oxford BioDynamics 1-Year Share Buyback Ratio Calculation

Oxford BioDynamics's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(1957.578 - 4290.911) / 1957.578
=-119.2%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -119.20 mean?
Oxford BioDynamics (OXBOF) has a 1-Year Share Buyback Ratio of -119.20 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #136 out of 146 companies in the Medical Diagnostics & Research industry, placing it in the top 93.2%.
Is Oxford BioDynamics' 1-Year Share Buyback Ratio too high?
Oxford BioDynamics' current 1-Year Share Buyback Ratio is -119.20. Based on the distribution chart, Oxford BioDynamics ranks #136 out of 146 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' 1-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #136 out of 146 companies for 1-Year Share Buyback Ratio. This places Oxford BioDynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 1-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Oxford BioDynamics and its competitors. Oxford BioDynamics's current 1-Year Share Buyback Ratio is -119.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 84% below its estimated fair value. The current 1-Year Share Buyback Ratio is -119.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current 1-Year Share Buyback Ratio is -119.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.